Cargando…
Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients
CR1447 (4-hydroxytestosterone, 4-OHT) binds to the androgen receptor and has antiproliferative activity in both ER-positive and ER-negative/AR-positive breast cancer cells in preclinical studies. The objective of this first-in man trial was to evaluate the safety and to determine the dose of CR1447,...
Autores principales: | Zweifel, Martin, Thürlimann, Beat, Riniker, Salome, Weder, Patrik, von Moos, Roger, Pagani, Olivia, Bigler, Martin, Rothgiesser, Karin M, Pilop, Christiane, Hawle, Hanne, Brauchli, Peter, Tapia, Coya, Schoenfeld, Wolfgang, Sessa, Cristiana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606553/ https://www.ncbi.nlm.nih.gov/pubmed/28814476 http://dx.doi.org/10.1530/EC-17-0174 |
Ejemplares similares
-
SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients
por: Vetter, Marcus, et al.
Publicado: (2022) -
Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99
por: Eppenberger-Castori, Serenella, et al.
Publicado: (2020) -
1447. Emergence of Avibactam Resistance in Multidrug-Resistant Enterobacteriaceae
por: Brennan-Krohn, Thea, et al.
Publicado: (2020) -
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
por: Schmid, Sabine, et al.
Publicado: (2019) -
A tale of excess: the curious case of the woman with 1447 emergency visits
por: Sagué Vilavella, M., et al.
Publicado: (2023)